IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

PartnershipProSense® Cryoablation SystemsPositive

AI Analysis

Summary

IceCure secured an exclusive distribution agreement for ProSense® Cryoablation Systems in the Netherlands. The cryoablation technology is advancing through Phase III in the THERMAC trial after achieving the highest complete ablation rate among evaluated thermal ablation technologies.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Exclusive distribution agreement for Netherlands

Importance:6/10

Sentiment:

0.60

distribution agreementcryoablationbreast cancerPhase IIINetherlandsthermal ablationcommercialization

Related Companies

$ICCM

Read the original article

Published by PR Newswire Biotech on August 24, 2026 11:50 AM

Read Original